BioCentury
ARTICLE | Clinical News

USL311: Phase I/II started

May 23, 2016 7:00 AM UTC

Upsher-Smith began an open-label, dose-escalation, international Phase I/II trial to evaluate once-weekly USL311 with or without lomustine every 6 weeks in 120 patients. The Phase I portion will enrol...